Anti-PDE4B / Phosphodiesterase 4B

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. PDE4B antibody detects Phosphodiesterase 4B, an enzyme that hydrolyzes cyclic AMP (cAMP) into AMP, terminating cAMP-dependent signaling. PDE4B belongs to the type 4 phosphodiesterase family, which provides fine control of intracellular cAMP concentrations. The PDE4B antibody is used in research focused on inflammation, neuroscience, and psychiatric disorders involving cAMP signaling dysregulation.PDE4B is encoded by the PDE4B gene on human chromosome 1p31.3. The protein exists in multiple isoforms ranging from 70 to 100 kilodaltons, all containing a catalytic domain, upstream conserved regions (UCR1 and UCR2), and regulatory sequences that determine localization and activation. PDE4B localizes to cytoplasmic and perinuclear regions and interacts with signaling complexes via A-kinase anchoring proteins (AKAPs).The PDE4B antibody identifies characteristic isoforms in western blot. Functionally, PDE4B hydrolyzes cAMP generated by G protein-coupled receptor activation, shaping responses to neurotransmitters, hormones, and immune stimuli. It regulates protein kinase A (PKA) activity and downstream transcription factors such as CREB.In immune cells, PDE4B modulates cytokine production and inflammatory responses. Inhibition of PDE4B enhances cAMP signaling, reducing pro-inflammatory cytokines like TNF-alpha and IL-6. In the central nervous system, PDE4B regulates neuronal excitability, memory, and emotional processing. Genetic and pharmacologic studies implicate PDE4B dysfunction in depression, schizophrenia, and addiction.PDE4B is a therapeutic target for anti-inflammatory and neuropsychiatric drugs. Selective inhibitors such as rolipram and roflumilast have been developed to modulate cAMP signaling. NSJ Bioreagents provides a validated PDE4B antibody optimized for its applications, supporting investigation into cyclic nucleotide metabolism, immune regulation, and neuronal signaling.